Baillie Gifford & Co
VIR icon

Baillie Gifford & Co’s Vir Biotechnology VIR Stock Holding History

Baillie Gifford & Co’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,383,029
Closed -$17.8M – 283
2024
Q3 		$17.8M Sell
2,383,029
-1,538,213
-39% -$13.4M 0.01% 186
2024
Q2 		$34.9M Sell
3,921,242
-25,823
-0.7% -$248K 0.03% 156
2024
Q1 		$40M Sell
3,947,065
-18,484
-0.5% -$188K 0.03% 156
2023
Q4 		$39.9M Sell
3,965,549
-6,022
-0.2% -$55K 0.03% 163
2023
Q3 		$37.2M Sell
3,971,571
-11,874
-0.3% -$169K 0.03% 159
2023
Q2 		$97.7M Sell
3,983,445
-2,581
-0.1% -$64.8K 0.08% 124
2023
Q1 		$92.8M Buy
3,986,026
+1,425
+0% +$36.4K 0.08% 123
2022
Q4 		$101M Buy
3,984,601
+5,944
+0.1% +$146K 0.11% 111
2022
Q3 		$76.7M Buy
3,978,657
+47,805
+1% +$1.22M 0.08% 128
2022
Q2 		$100M Sell
3,930,852
-16,308
-0.4% -$381K 0.1% 121
2022
Q1 		$102M Buy
3,947,160
+31,659
+0.8% +$939K 0.07% 138
2021
Q4 		$164M Buy
3,915,501
+15,809
+0.4% +$619K 0.09% 118
2021
Q3 		$170M Buy
3,899,692
+50,183
+1% +$2.17M 0.09% 122
2021
Q2 		$182M Buy
3,849,509
+32,361
+0.8% +$1.47M 0.09% 128
2021
Q1 		$196M Buy
3,817,148
+72,200
+2% +$3.89M 0.11% 117
2020
Q4 		$100M Buy
3,744,948
+29,060
+0.8% +$945K 0.06% 131
2020
Q3 		$128M Buy
3,715,888
+252,686
+7% +$10.9M 0.09% 112
2020
Q2 		$142M Buy
3,463,202
+3,333,333
+2,567% +$112M 0.11% 103
2020
Q1 		$4.45M Sell
129,869
-370,131
-74% -$9.95M ﹤0.01% 184
2019
Q4 		$6.29M Buy
+500,000
New +$6.7M 0.01% 183

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Baillie Gifford & Co's VIR Position: Q4 2024 in Review

Baillie Gifford & Co sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 2,383,029 shares — an estimated $17.8M sold.

Baillie Gifford & Co first reported a position in VIR in Q4 2019 and held it in 20 quarters. The position peaked at $196M in Q1 2021. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

  • Baillie Gifford & Co reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Baillie Gifford & Co sold 2,383,029 Vir Biotechnology shares in Q4 2024, an estimated $17.8M.
  • Baillie Gifford & Co first reported a position in Vir Biotechnology in Q4 2019 and held it in 20 quarters.
  • Baillie Gifford & Co's Vir Biotechnology position peaked at $196M in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Baillie Gifford & Co's 13F filing for Q4 2024, filed 31 Jan 2025.